Aclaris Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at the following conferences:

• Dr. Neal Walker, President and Chief Executive Officer, together with members from the Company’s R&D team, will present a company overview at SVB Leerink’s 13th Annual POLARxPRESS Bus Tour in New York, New York on Thursday, November 21, 2019. The R&D team will include:
  • Joseph Monahan, Ph.D. - EVP R&D (Head of Discovery)
  • Walter Smith - SVP, R&D
  • Paul Changelian, Ph.D. - VP, Biology
  • Jon Jacobsen, Ph.D. - VP, Chemistry
  • Dr. David Gordon - Chief Medical Officer
• Dr. Walker will also present a company overview at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 3:05 PM ET at the Four Seasons Hotel in Boston, Massachusetts. A live audio webcast of the presentation may be accessed through the Company's web site, www.aclaristx.com, on the 'Events' section. An archived version of the presentation will be available for 30 days.

About Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes one late-stage investigational drug candidate and a pipeline powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.

Aclaris ContactMichael Tung, M.D.Corporate Strategy/Investor Relations484-329-2140[email protected]

You May Also Be Interested In

• Canaccord Starts Aclaris Therapeutis (ACRS) at Buy
• MacLean Power Systems to Acquire Delta Star
• The Housing Market's Supply Problem Has an Assembly-Line Answer, and an Agreement Covering 1,500-Homes Will Put It to the Test